» Articles » PMID: 32113834

IL-6/STAT3 Mediates the HPV18 E6/E7 Stimulated Upregulation of MALAT1 Gene in Cervical Cancer HeLa Cells

Overview
Journal Virus Res
Specialty Microbiology
Date 2020 Mar 2
PMID 32113834
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

MALAT1, a long non-coding RNA, is highly expressed in cervical cancer cells and plays an important role in the development of cervical cancer. However, the mechanism for the excessive expression of MALAT1 in cervical cancer remains unclear. High-risk HPVs are causative agents of cervical cancer and the IL-6/STAT3 signaling is closely correlated with the development of various cancers including cervical cancer. In this study, the roles of HPV18 E6/E7 and IL-6/STAT3 in the regulation of MALAT1 transcription in cervical cancer cells were investigated. It was found that HPV18 E6/E7 activated the IL-6/STAT3 signaling and, in reciprocal, IL-6/STAT3 strengthened HPV18 E6/E7 expression in HeLa cells. Both HPV18 E6/E7 and IL-6/STAT3 were involved in MALAT1 expression and they worked synergistically in the upregulation of MALAT1 gene. With luciferase reporter assays, a STAT3-binding sequence in the enhancer region of MALAT1 gene was demonstrated to be crucial for the IL-6- or STAT3-induced MALAT1 promoter activation. Taken together, our data suggest that IL-6/STAT3 mediates the HPV18 E6/E7 stimulated upregulation of MALAT1 gene in cervical cancer HeLa cells.

Citing Articles

Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling.

Shi C, Bopp T, Lo H, Tkaczuk K, Lin J Curr Oncol. 2024; 31(10):5737-5751.

PMID: 39451730 PMC: 11505662. DOI: 10.3390/curroncol31100426.


Multi-omics analysis of macrophage-associated receptor and ligand reveals a strong prognostic signature and subtypes in hepatocellular carcinoma.

Zhao Y, Chen C, Chen K, Sun Y, He N, Zhang X Sci Rep. 2024; 14(1):12163.

PMID: 38806553 PMC: 11133315. DOI: 10.1038/s41598-024-62668-x.


Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance.

Xu D, Wang W, Wang D, Ding J, Zhou Y, Zhang W Noncoding RNA Res. 2024; 9(2):388-406.

PMID: 38511067 PMC: 10950606. DOI: 10.1016/j.ncrna.2024.01.015.


HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice.

Long J, Chen X, He M, Ou S, Zhao Y, Yan Q Nat Commun. 2024; 15(1):2271.

PMID: 38480731 PMC: 10937927. DOI: 10.1038/s41467-024-46558-4.


Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.

Ye J, Zheng L, He Y, Qi X MedComm (2020). 2023; 4(5):e368.

PMID: 37719443 PMC: 10501338. DOI: 10.1002/mco2.368.